LGB Forge Ltd, Heubach Colorants India Ltd, Beekay Steel Industries Ltd and Pondy Oxides & Chemicals Ltd are among the other gainers in the BSE’s ‘B’ group today, 21 June 2024.

Hester Biosciences Ltd leads gainers in ‘B’ group

Hester Biosciences posted standalone net profit of ₹6.2 crore for the quarter ended March 31, 2023,

Hester Biosciences to repurpose BSL-3 facility as Covid vaccine demand tapers off

Acquires technology from ICAR-NIHSAD to develop Low Pathogenic Avian Influenza (H9N2 strain) inactivated vaccine

Hester Biosciences to develop inactivated influenza vaccine for poultry

Hester Biosciences rose 2% to Rs 1839.95 after the company announced the acquisition of technology from ICAR - NIHSAD to develop a low pathogenic avian influenza (H9N2 strain) inactivated vaccine for poultry.

HesterBio gains on acquiring technology for H9N2 avian influenza virus vaccine from ICAR - NIHSAD

ICICI Direct recommended hold rating on Hester Biosciences with a target price of Rs 2070 in its research report dated November 08, 2022.

Hold Hester Biosciences; target of Rs 2070: ICICI Direct

Jammu and Kashmir Bank Ltd, Neuland Laboratories Ltd, Indiabulls Housing Finance Ltd and Varun Beverages Ltd are among the other losers in the BSE’s ‘A’ group today, 27 September 2022.

Hester Biosciences Ltd leads losers in ‘A’ group

At 1:30 pm, the scrip was quoting at Rs 2,135 on the National Stock Exchange.

Hester Biosciences boosted by strong demand for goat pox vaccine

Hester Biosciences surged 10% to Rs 2162.05 after the company said it has adequate supply of Goat Pox Vaccine in India to immunize cattle against Lumpy Skin disease.

Hester Bio spurts on ensuring adequate supply of Goat Pox Vaccine in India

Hester Biosciences Q1 Review - Weak Poultry Performance Continues To Weigh On Numbers: ICICI Direct

ICICI Direct recommended reduce rating on Hester Biosciences with a target price of Rs 2015 in its research report dated August 16, 2022.

Reduce Hester Biosciences; target of Rs 2015: ICICI Direct

Hester Biosciences Company expects to commission Covid vaccine facility in Q3

Hester Biosciences Q1 net down 68% on lower vaccine sales

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.

Hester Biosciences Ltd